Drug Watch

Latest News

Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis

May 15th 2025

Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.

Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis
Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis

May 9th 2025

Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial
Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial

May 8th 2025

FDA Approves First Gene Therapy for RDEB
FDA Approves First Gene Therapy for RDEB

April 29th 2025

FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria

April 18th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.